Unregistered Sales of Equity Securities and Use of Proceeds.
−Removed: On June 2, 2022, we granted our Chief Executive Officer an option to purchase 950,209 shares of our common stock, and on July 18, 2022, we granted our Chief Medical Officer an option to purchase 171,602 shares of our common stock, each as an inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
−Removed: No underwriters were involved in the foregoing issuances of securities.
+Added: On July 18, 2022, we granted our Chief Medical Officer an option to purchase 171,602 shares of our common stock as an inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
+Added: No underwriters were involved in the foregoing issuance of securities.
The securities were issued pursuant to Section 4(a)(2) under the Securities Act of 1933, as amended, relating to transactions by an issuer not involving any public offering.
−Removed: The recipients either received adequate information about us or had access, through other relationships, to such information.
−Removed: The stock options are scheduled to become exercisable as to 25% of the shares underlying the options on the first anniversary of their respective dates of grant, and as to an additional 2.0833% of the shares underlying the options at the end of each successive month following such date, subject to the recipient’s continued service.
−Removed: The option granted to our Chief Executive Officer has an exercise price of $11.54 per share, and the option granted to our Chief Medical Officer has an exercise price of $14.99 per share.
+Added: The recipient either received adequate information about us or had access, through other relationships, to such information.
+Added: The stock option is scheduled to become exercisable as to 25% of the shares underlying the options on the first anniversary of the date of grant, and as to an additional 2.0833% of the shares underlying the option at the end of each successive month following such date, subject to the recipient’s continued service.
+Added: The option has an exercise price of $14.99 per share.
Exhibit Index
Description of Exhibit
−Removed: Employment Offer Letter, dated April 13, 2022, between the Registrant and Gilmore O’Neill.
−Removed: Amendment to Employment Offer Letter, dated April 13, 2022, between the Registrant and James C.
−Removed: Employment Offer Letter, dated June 14, 2022, between the Registrant and Baisong Mei.
−Removed: Amendment to RSU Agreement, dated May 24, 2022, between the Registrant and James C.
Rule 13a-14(a) Certification of Principal Executive Officer
1 unchanged sentence
Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C.
−Removed: The following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, formatted in Inline XBRL (eXtensible Business Reporting Language):
−Removed: (i) Consolidated Balance Sheets (unaudited), (ii) Consolidated Statements of Operations (unaudited), (iii) Consolidated Statements of Comprehensive Loss (unaudited), (iv) Consolidated Statements of Stockholders’ Equity (unaudited), (v) Consolidated Statements of Cash Flows (unaudited) and (vi) Notes to Condensed Consolidated Financial Statements (unaudited), tagged as blocks of text and including detailed tags.
−Removed: The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, formatted in Inline XBRL.
+Added: The following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, formatted in Inline XBRL (eXtensible Business Reporting Language):
+Added: (i) Condensed Consolidated Balance Sheets (unaudited), (ii) Condensed Consolidated Statements of Operations (unaudited), (iii) Condensed Consolidated Statements of Comprehensive Loss (unaudited), (iv) Condensed Consolidated Statements of Stockholders’ Equity (unaudited), (v) Condensed Consolidated Statements of Cash Flows (unaudited) and (vi) Notes to Condensed Consolidated Financial Statements (unaudited), tagged as blocks of text and including detailed tags.
+Added: The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, formatted in Inline XBRL.
* Filed herewith
3 unchanged sentences
EDITAS MEDICINE, INC.
−Removed: August 3, 2022
+Added: November 2, 2022
/s/ Michelle Robertson
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.